Keywords: Contrast Agents, Cancer
Motivation: Due to the high malignancy of triple-negative breast cancer and the lack of effective treatment methods, it is necessary to develop brand-new, safe and efficient treatment approaches.
Goal(s): MM nanoparticles could mediate photodynamic therapy, release oxygen and small molecule drugs to enhance the PDT efficacy in situ of the tumor, and could be monitored by MR in real time upon the release of Mn²⁺ from tumor microenvironment-responsive MnO₂ nanoparticles.
Approach: Animal model validation and 3.0T MR scan in vivo and in vitro validation
Results: In vitro and in vivo studies have shown that MM can mediate PDT and achieve real-time MR monitoring.
Impact: Nano carriers (MM) exhibit significant MRI - monitoring ability in vivo during the treatment process, with a longer imaging window and good PDT effects. These MRI - related features show great potential as a therapeutic - diagnostic platform for TNBC treatment using nanomedicine.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords